Object's details: Finerenone as a therapeutic option for managing chronic kidney disease (CKD) linked to type 2 diabetes (T2D) and his other potential use. A summary of current research findings

Provider:Akademicka Platforma Czasopism

Description

Title:
Finerenone as a therapeutic option for managing chronic kidney disease (CKD) linked to type 2 diabetes (T2D) and his other potential use. A summary of current research findings
Creator:
Kubuj, Cezary;
Adaśko, Grzegorz;
Świda, Michał;
Bazarewicz, Jakub;
Mazur, Urszula;
Siwik, Marcin;
Dmowski, Daniel;
Michalska, Anna;
Ogonowska, Paulina;
Waszak, Julia
Description:
Introduction: Chronic kidney disease (CKD) is a common, often late-diagnosed and progressive condition associated with increased morbidity and mortality, mainly due to elevated cardiovascular risk. Diabetes is the one of the leading causes of CKD. Due to the significant role that excessive mineralocorticoid receptor (MR) activation plays in the development of diabetic kidney disease (DKD), new therapies that target this pathway, are being investigated. Finerenone is a non-steroidal selective antagonist that reduces inflammation and fibrosis by blocking MR overactivity in the kidneys, heart, and blood vessels. Materials and Methods: This review is based on a comprehensive analysis of studies on the use of finerenone in patients with CKD and type 2 diabetes (T2D). Additionally, this article explores the potential applications of finerenone. The review was developed using a PubMed database and ClinicalTrials.gov. Results: The results of the FIDELIO-DKD and FIGARO-DKD trials, as well as the FIDELITY pooled analysis, showed that finerenone significantly improved renal and cardiovascular outcomes. They also showed that although hyperkalemia is a major adverse effect of finerenone treatment, the therapy is safe with appropiate monitoring and dose adjustment. In addition, its possible beneficial effects are in non-diabetic CKD, heart failure with preserved (HFpEF) and mildly reduced (HFmrEF) ejection fraction, advanced of CKD with lower estimated glomerular filtration rate (eGFR), and diabetic retinopathy. Conclusion: Clinical studies have confirmed that finerenone is a valuable addition to nephroprotective and cardioprotective strategies in the management of CKD associated with T2D, as reflected in latest clinical guidelines. Its safety profile is generally acceptable. Ongoing clinical trials will help clarify whether the approved indications for finerenone can be extended to non-diabetic CKD or additional clinical settings.
Object availability:
free access
Rights: https://creativecommons.org/licenses/by-nc-sa/4.0 ;
Prawa autorskie (c) 2025 Cezary Kubuj, Grzegorz Adaśko, Michał Świda, Jakub Bazarewicz, Urszula Mazur, Marcin Siwik, Daniel Dmowski, Anna Michalska, Paulina Ogonowska, Julia Waszak
Date:
2025.07.11
Type:
info:eu-repo/semantics/article;
info:eu-repo/semantics/publishedVersion
Language:
English
Source:
Quality in Sport; Tom 43 (2025); 62411;
Quality in Sport; Vol. 43 (2025); 62411;
2450-3118
Format:
application/pdf
Publisher:
University Center for Sports Research, Nicolaus Copernicus University, Torun, Poland
Relation: https://apcz.umk.pl/QS/article/view/62411/43219
Subject:
finerenone;
chronic kidney disease (CKD);
type 2 diabetes (T2D);
diabetic kidney disease (DKD);
mineralocorticoid receptor (MR)
Identifier: https://apcz.umk.pl/QS/article/view/62411
Data provider:
Akademicka Platforma Czasopism

Similar objects

Finerenone as a therapeutic option for managing chronic kidney disease (CKD) linked to type 2 diabetes (T2D) and his other potential use. A summary of current research findings

Date:2025.07.11

Type:text

The Impact of Physical Activity on Treatment Outcomes in Patients with Type 2 Diabetes

Date:2024.12.12

Type:text

The Application of Incretin-Based Pharmacotherapy in the Contemporary Management of Type 2 Diabetes: A Review of the Literature

Date:2025.01.22

Type:text

The Use of angiotensin converting enzyme inhibitors in chronic kidney disease - a review of the literature

Date:2023.04.20

Type:text

Mpox (Monkeypox): A Comprehensive Review of Etiology, Epidemiology, Transmission, Clinical Presentation, Diagnosis, Treatment, and Prevention

Date:2025.07.13

Type:text

The Impact of Physical Activity on Mental Health of Children and Adolescents: A Comprehensive Review of Current Research and Clinical Implications

Date:2025.07.11

Type:text

Duchenne muscular dystrophy - disease characterization and emergent genetic therapy - literature review

Date:2025.07.10

Type:text

An attempt to use the serum concentration of the phosphate (Pi) and the Ca x P productas markers of the progression of chronic kidney disease in cats

Creator:Sławuta, P. | Kumiega, E. | Sikorska-Kopyłowicz, A. | Sapikowski, G. | Kurosad, A.

Date:2019.12.27

Type:image

Federacja Bibliotek Cyfrowych

Object's details: Finerenone as a therapeutic option for managing chronic kidney disease (CKD) linked to type 2 diabetes (T2D) and his other potential use. A summary of current research findings

Description

Similar objects